Editas Medicine (EDIT) Gains from Investment Securities (2015 - 2016)
Editas Medicine's (EDIT) quarterly Gains from Investment Securities came in at $87000.0 in Q1 2016, up 569.23% on a QoQ basis from $13000.0 in Q3 2015.
Editas Medicine (EDIT) Gains from Investment Securities (2015 - 2016) Analysis & Trends
Editas Medicine (EDIT) has 2 years of Gains from Investment Securities data on file, last reported at $87000.0 in Q1 2016.
- On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $87000.0 in Q1 2016; TTM through Dec 2016 was $87000.0, a N/A change from a year earlier, with the FY2016 full-year figure at $87000.0, changed N/A from the prior year.
- Gains from Investment Securities for Q1 2016 stood at $87000.0, up from $13000.0 in the prior quarter.
- Over the last five years, Gains from Investment Securities for EDIT reached as high as $87000.0 in Q1 2016 and fell as low as $13000.0 in Q3 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Editas Medicine | 245.95 Mn | 99.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 87,000.00 |
| Mar 31, 2016 | 87,000.00 |
| Sep 30, 2015 | 13,000.00 |
| Sep 30, 2015 | 13,000.00 |